Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | IMM-1-104 |
| Trade Name | |
| Synonyms | IMM 1-104|IMM1-104 |
| Drug Descriptions |
IMM-1-104 inhibits MEK1 and MEK2, resulting in decreased downstream ERK1/2 activation and potentially leading to inhibition of tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P252). |
| DrugClasses | MEK inhibitor (Pan) 27 MEK1 Inhibitor 27 MEK2 Inhibitor 25 |
| CAS Registry Number | NA |
| NCIT ID | C192810 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Dabrafenib + IMM-1-104 | Dabrafenib IMM-1-104 | 0 | 1 |
| Fluorouracil + IMM-1-104 + Irinotecan + Leucovorin + Oxaliplatin | Fluorouracil IMM-1-104 Irinotecan Leucovorin Oxaliplatin | 0 | 1 |
| Gemcitabine + IMM-1-104 + Nab-paclitaxel | Gemcitabine IMM-1-104 Nab-paclitaxel | 0 | 1 |
| IMM-1-104 | IMM-1-104 | 2 | 1 |
| IMM-1-104 + Pembrolizumab | IMM-1-104 Pembrolizumab | 0 | 1 |